The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) frequently presents as advanced stage with poor prognosis and high mortality. Systemic treatment is the treatment of choice for advanced disease. In 2007, the first multi-kinase inhibitor (MKI) sorafenib was approved and shown to modestly prolong overall survival (OS)....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Korean Liver Cancer Association,
2023-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|